Clinical Characteristics of Patients with Bronchioloalveolar Carcinoma: A Retrospective Study of 44 Cases |
Dirican, Nigar
(Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital)
Baysak, Aysegul (Department of Chest Diseases, Faculty of Medicine, Izmir University) Cok, Gursel (Department of Chest Diseases, Faculty of Medicine, Ege University) Goksel, Tuncay (Department of Chest Diseases, Faculty of Medicine, Ege University) Aysan, Tulin (Department of Chest Diseases, Faculty of Medicine, Ege University) |
1 | AJCC Cancer Staging Manual, Seventh Edition (2010). published by Springer NewYork, Inc |
2 | Barsky SH, Cameron R, Osann KE, et al (1994). Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer, 73, 1163-70. DOI ScienceOn |
3 | Bria E, Milella M, Sperduti I, et al (2009). A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-smallcell lung cancer. Lung Cancer, 66, 365-71. DOI ScienceOn |
4 | Brugger W, Triller N, Blasinska-Morawiec M, et al (2011). Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol, 29, 4113-20. DOI ScienceOn |
5 | Cadranel J, Gervais M, Wislez P, et al (2011). IFCT-0504 trial: Mucinous and nonmucinous cytologic subtypes interaction effect in first-line treatment of advanced broncioloalveolar carcinoma by erlotinib or carboplatin/paclitaxel. J Clin Oncol, 29, 481. DOI |
6 | Fukui T, Mori S, Yokoi K, et al (2006). Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol, 1, 1220-5. |
7 | Groome PA, Bolejack V, Crowley JJ, et al (2007). The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2, 694-705. DOI |
8 | Hoang T, Xu R, Schiller JH, et al (2005). Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol, 23, 175-83. DOI ScienceOn |
9 | Jemal A, Bray F, Center MM, et al (2011).Global cancer statistics. Cancer J Clin, 61, 69-90. DOI |
10 | Johnson ML, Sima CS, Chaft J, et al (2013). Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer, 119, 356-62. DOI ScienceOn |
11 | Kawaguchi T, Takada M, Kubo A, et al (2010). Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol, 5, 620-30. |
12 | Kris MG, Giaccone G, Davies A, et al (2006). Systemic therapy of bronchioloalveolar carcinoma: Results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. J Thorac Oncol, 1, 32-6. DOI |
13 | Lee BR, Yu JY, Ban HJ, et al (2012). Analysis of patients with hemoptysis in a tertiary referral hospital. Tuberc Respir Dis, 73, 107-14. DOI ScienceOn |
14 | Lee JG, Lee CY, Park IK, et al (2008). Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg, 85, 211-5. DOI ScienceOn |
15 | Miller VA, Hirsch FR, Johnson DH (2005). Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. J Clin Oncol, 23, 3288-93. DOI ScienceOn |
16 | Read WL, Page NC, Tierney RM, et al (2004). The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer, 45, 137-42. DOI ScienceOn |
17 | Shaw AT, Kim DW, Nakagawa K, et al (2012). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med, 368, 2385-94. |
18 | Rosell R, Carcereny E, Gervais R, et al (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 13, 239-46. DOI ScienceOn |
19 | Rusch VW, Tsuchiya R, Tsuboi M, et al (2006). Surgery for bronchioloalveolar carcinoma and "very early" adenocarcinoma: An evolving standard of care? J Thorac Oncol, 1, 27-31. DOI |
20 | Scagliotti GV, Smit E, Bosquee L, et al (2005). A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer, 50, 91-6. DOI ScienceOn |
21 | Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. DOI ScienceOn |
22 | Travis WD, Brambilla E, Noguchi M, et al (2011). International association for the study of lung cancer/american thoracic society/european respiratory society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc, 8, 381-5. |
23 | West HL, Crowley JJ, Vance RB, et al (2005). Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Ann Oncol, 16, 1076-80. DOI ScienceOn |
24 | Zhou C, Wu YL, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol, 12, 735-42. DOI ScienceOn |